Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy

Vyshak Alva Venur; Monika Joshi; Kenneth G Nepple; Yousef Zakharia

doi:10.2147/DDDT.S110209

Back

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy

Journal article

Open access

Peer reviewed

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy

Vyshak Alva Venur, Monika Joshi, Kenneth G Nepple and Yousef Zakharia

Drug design, development and therapy, Vol.11, pp.1175-1182

2017

DOI: 10.2147/DDDT.S110209

PMCID: PMC5395273

PMID: 28442891

Files and links (1)

url

https://doi.org/10.2147/DDDT.S110209View

Published (Version of record) Open Access

Abstract

Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC.

Antineoplastic Agents - chemical synthesis

Humans

Kidney Neoplasms - immunology

Antibodies, Monoclonal - therapeutic use

Antineoplastic Agents - therapeutic use

Clinical Trials as Topic

Antineoplastic Agents - chemistry

Carcinoma, Renal Cell - immunology

Animals

Drug Design

Carcinoma, Renal Cell - drug therapy

Kidney Neoplasms - drug therapy

Antibodies, Monoclonal - chemistry

Details

Title: Subtitle: Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
Creators: Vyshak Alva Venur - Division of Hematology Oncology and Bone Marrow Transplant, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA
Monika Joshi - Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA
Kenneth G Nepple - Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
Yousef Zakharia - Division of Hematology Oncology and Bone Marrow Transplant, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA
Resource Type: Journal article
Publication Details: Drug design, development and therapy, Vol.11, pp.1175-1182
DOI: 10.2147/DDDT.S110209
PMID: 28442891
PMCID: PMC5395273
NLM abbreviation: Drug Des Devel Ther
ISSN: 1177-8881
eISSN: 1177-8881
Publisher: New Zealand
Language: English
Date published: 2017
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Urology; Internal Medicine
Record Identifier: 9984051883702771

Metrics

13 Record Views

12 Times Cited - Web of Science